MOST NOTEWORTHY: American Eagle, Hologic and British Airways were today's noteworthy downgrades:

• Friedman Billings downgraded American Eagle (NYSE: AEO) to Underperform from Market Perform citing slowing top-line growth, difficult macro-environment, and the challenging women's category.
  
• Soleil cut Hologic (NASDAQ: HOLX) to Hold from Buy as it believes the cancellation of the FDA Radiological Devices Panel means a further delay in the tomosynthesis pre-market approval application.
  
• ABN downgraded shares of British Airways (Other OTC: BAIRY) to Sell from Hold as it believes the recent rally in the face of higher oil prices is unjustified. Shares were also lowered at Deutsche Bank to Sell from Buy as it believes the company may not be able to raise ticket prices enough to offset higher fuel costs.

OTHER DOWNGRADES:

• ArthroCare (NASDAQ: ARTC) was cut to Accumulate from Buy at ThinkPanmure.
  
• ING downgraded J Sainsbury (Other OTC: JSAIY) to Sell from Hold.
  
• RBC Capital downgraded Ceragon Networks (NASDAQ: CRNT) to Sector Perform from outperform.

Hologic (NASDAQ: HOLX), a medical imaging company, is recently trading down 71 cents to $20.22 in pre-open trading.

Soleil says: "downgrading HOLX from Buy to Hold following our confirmation from the FDA that the tentative date for Radiological Devices Panel (8.12.08) has been canceled-an action which reads negative for HOLX."

HOLX over all option implied volatility of 46 is above its 26-week average of 43 according to Track Data, suggesting larger price uncertainty.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

In a choppy/consolidating (or perhaps worse) market, discretion dictates that one look for companies where the demographics are running in the company's favor. Health care services in the United States is one sector, and in this category Hologic is worth an evaluation.

Hologic (NASDAQ: HOLX) manufactures mammography tests/products, workstations, and detection systems, as well as cervical cancer screening systems, among other health care service business lines.

Analysts see solid-to-robust growth for HOLX on favorable demographic trends and increased health education awareness to undergo regular, as-required tests for the conditions HOLX screens. Margins remain solid in both the breast cancer and cervical cancer detection areas, with promising opportunities to increase market share. The Reuters F2007/F2008 EPS consensus estimates for HOLX are $1.69/$2.25.

The risks: Negative changes to Medicare and/or private insurer reimbursement rates would hurt HOLX's results, if clinics consequently reduce tests with machines/devices manufactured by HOLX. Analysts also are monitoring intensifying competition across HOLX's revenue streams.

The First Call mean rating for HOLX is: Buy. [13 firms.] Mean 2008 target: $73.00. [high: $77, low: $65.]

Stock Analysis: Hologic is a moderate-risk stock not suitable for low-risk investors. Investors with an investment horizon longer than two years should be rewarded from HOLX's shares. Sell / Stop Loss if you were to purchase shares in this company: $42.

DISCLOSURE: Joseph Lazzaro has no positions in stocks. In addition to private real estate holdings, he owns corporate and municipal bonds, and cash certificates of deposit.

For 25 years, Steven Halpern, editor of TheStockAdvisors.com, has surveyed the leading financial newsletter advisors asking for their favorite stocks for the coming year. This article is one of 100+ ideas in the Best Stocks for 2008 report.

"Hologic, Inc. (NASDAQ: HOLX), my top more conservative idea for 2008, is fast becoming the 'Amazon' of women's health care," says Benson George, editor of Top Stocks Insights.

"The company, which specializes in diagnostic and medical imaging systems, bought complementary Cytyc Corp. in October, making Hologic the warrior of reckoning in the growing women's health market.

Hologic develops products for mammography and breast care, osteoporosis assessment and general use radiology. Cytyc's products cover a range of cancers and women's health concerns, including cervical cancer screening, prenatal diagnostics and partial breast radiation therapy.

"The combined company offers a broad and diversified mix of products and services focused only on women's health -- a multi-billion-dollar market growing 16% compounded annually.

TheStreet.com's Jim Cramer says that now, teetering financials and homebuilders will topple and safety plays will rule. Ouch.

Couple of tough days ahead. We were overbought going into this Fed decision; now we will have to pay for it, and pay for it big. We have to lose a lot that we gained, expecting that the Fed would work hand-in-hand with the Treasury Department to get us out of this jam.

But that's not going to happen now. You can see what will happen. They will kill the banks again. The fundraising that was going on will be halted. We will get some failures. The homebuilder credit lines? Some will not be extended.

Hologic (NASDAQ: HOLX) develops, manufactures and supplies diagnostic, medical imaging and radiology systems. The Radiological Society of North America (RSNA) 2007 Annual Meeting is this week in Chicago at McCormick Place. CIBC says "HOLX maintains Strong lead over competition." HOLX overall option implied volatility of 38 is near its 26-week average according to Track Data, suggesting non-directional risk.

Daily Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

TheStreet.com's Jim Cramer says that as counterintuitive as it seems, there are many stocks that will rise despite this huge bad news.

We're back in 1990 again. That was when commercial construction threatened to wipe out the U.S. banking system and the S&P 500 went down 13% in a heartbeat between the spring and the fall.

I trotted out this analogy in the summer to explain what a disaster could look like if the Fed, which at that time knew nothing, didn't do anything or, heaven forbid, did what the clueless Bill Poole wanted them to do, and tighten.

The market's been fighting with 1990 ever since. When I read about the losses and the need for the banks and the insurers to shore up capital -- $7.9 billion for Merrill, Dougie? Say it ain't so! -- I think to myself, "Oh my, it is 1990 when funding became a problem for every major bank." (Tremendous credit to my friend Doug Kass for flagging this.)

MOST NOTEWORTHY: VMWare, Validus Holdings and Hologic were today's noteworthy initiations:

• VMWare Inc (NYSE: VMW) was initiated by a host of firms: Banc of America believes the current valuation captures most of the upside potential, and started shares with a Neutral rating and $75 target. Wachovia started shares with a Market Perform rating and Deutsche Bank started shares with a Hold rating and $80 target on valuation. The stock was also started with a Buy rating and $92 target at UBS, with a Buy rating and $100 target at Citigroup and with an Overweight rating at JP Morgan and with a Neutral rating at Merrill Lynch.
  
• Validus Holdings (NYSE: VR) was started with a Buy rating and $29 target at UBS on valuation and benefits from the Talbots (NYSE: TLB) acquisition. Shares were also initiated at JP Morgan with a Neutral rating.
  
• CIBC resumed coverage of Hologic Inc (NASDAQ: HOLX) with a Sector Outperformer rating and $77 target as the firm is positive on Hologic's merger with Cytyc Corporation (NASDAQ: CYTC) and views it as one of the top mid-cap stories in the coming year.

OTHER INITIATIONS:

• B. Riley initiated shares of EuroBancshares (NASDAQ: EUBK) with a Buy rating and $10 target.
  
• Rodman resumed coverage of Ziopharm Oncology Inc (NASDAQ: ZIOP) with a Market Outperform rating and $8 target.
  
• Citigroup started shares of Timken Company (NYSE: TKR) with a Buy rating and $43 target.
  
• MercadoLibre Inc (NASDAQ: MELI) was initiated with a Sector Perform rating and $39 target at RBC Capital.

MOST NOTEWORTHY: In addition to Genomic Health (GHDX) and Intercontinental Hotels Group (IHG), airliners Continental Airlines (CAL) and ExpressJet Holdings (XTJ) were some of today's most notable initiations:

• RBC Capital Markets started Genomic Health Inc (NASDAQ: GHDX) with an Underperform rating, with a $17 target. The firm views shares as fairly valued and believes competitive noise and FDA concerns will weigh on shares.

• HSBC started Intercontinental Hotels (NYSE: IHG) with an Overweight rating, believing asset sales and stronger than expected room growth could prove near-term positive catalysts.

• Soliel started both Continental Airlines (NYSE: CAL) and ExpressJet Holdings Inc (NYSE: XJT) with Sell ratings.

OTHER INITIATIONS:

• William Blair started Alexion Pharmaceuticals (NASDAQ: ALXN) with an Outperform rating. They believe Alexion's lead compound, Soliris, is the key driver of shareholder value, and they believe the company is well positioned to receive final FDA approval.

• Bear Stearns initiated Baldor Electric Company (NYSE: BEZ) with an Outperform rating.

• RBC initiated Hologic, Inc (NASDAQ: HOLX) with an Outperform rating.

• Citigroup started GMarket Inc (NASDAQ: GMKT) with a Sell rating and $18 target, citing valuation.

• Drew Industries, Inc (NYSE: DW) was initiated with a Buy rating and $35 target at Ferris Baker Watts.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).